Stoke Therapeutics is the latest biotech company to debut on Wall Street, raising $142 million to test an experimental therapy for a rare form of epilepsy.
Stoke does not yet have any human data to show investors, but the Bedford, MA, company was still able to sell more shares than it planned—and at a higher price. Tuesday evening, the company sold approximately 7.8 million shares for $18 apiece. Stoke had planned to offer 6.7 million shares in the range of $14 to $16 each. Those shares are expected to begin trading on the Nasdaq exchange Wednesday under the stock symbol “STOK.”… Read more »
UNDERWRITERS AND PARTNERS
